Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Asset Writedowns and Impairment (2019 - 2025)

Fortress Biotech (FBIO) has 8 years of Asset Writedowns and Impairment data on record, last reported at -$195000.0 in Q2 2025.

  • For Q2 2025, Asset Writedowns and Impairment fell 233.56% year-over-year to -$195000.0; the TTM value through Sep 2025 reached -$307000.0, down 140.08%, while the annual FY2024 figure was $516000.0, 18.62% up from the prior year.
  • Asset Writedowns and Impairment reached -$195000.0 in Q2 2025 per FBIO's latest filing, down from $195000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $2.8 million in Q2 2023 and bottomed at -$2.4 million in Q3 2023.
  • Average Asset Writedowns and Impairment over 5 years is $55500.0, with a median of $8000.0 recorded in 2022.
  • Peak YoY movement for Asset Writedowns and Impairment: surged 5650.0% in 2021, then tumbled 24410.0% in 2023.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $115000.0 in 2021, then crashed by 108.7% to -$10000.0 in 2022, then crashed by 470.0% to -$57000.0 in 2023, then crashed by 438.6% to -$307000.0 in 2024, then soared by 36.48% to -$195000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were -$195000.0 in Q2 2025, $195000.0 in Q1 2025, and -$307000.0 in Q4 2024.